At its Investor Day event, Pfizer (PFE -0.1%) reviewed its pipeline of 89 projects spread across six therapeutic areas. Four programs are in registration and 23 are in Phase 3 development.
27 key programs highlighted.
Revenue CAGR of at least 6% over the next five years.
Highlights pertaining to COVID-19:
Stability data on BNT162b2 supports five-storage at refrigerated (2-8 °C) temperature.
Phase 1 data two weeks after the second shot showed neutralizing geometric mean titers higher than convalescent sera.
Limited blinded tolerability data from ongoing Phase 3 study showed mild-to-moderate tolerability profile.
Application filed with FDA to expand Phase 3 enrollment to ~44K subjects, allowing for recruitment of new populations. Current enrollment is north of 29K.
Data readout on efficacy likely by end of October.
Initiated a Phase 1b study of PF-07304814, an intravenously administered phosphate prodrug that metabolizes into the active compound PF-00835321 which has demonstrated to be a very potent inhibitor of the SARS-Cov2 3CL protease in preclinical studies.
Related ticker: BioNTech SE (BNTX -1.3%)